How We Do It

Developing first-in-class chemical inhibitors requires excellent collaboration across a broad range of disciplines including protein biochemistry, cell biology, screening, structural biology, medicinal chemistry, pharmacology, animal models, and in-the-trenches medical insight.  The Longwood medical area is one of the few places that brings all these ingredients into a single pot.  The Gray lab uses kinase-focused libraries designed using structure-guided inhibitor design in conjugation with kinome-wide selectivity profiling using enzymatic, binding and chemical proteomic technologies .  We then form collaborative project teams with cell biologists and translational researchers interested in these kinases or in the pathways that they function in order to further the development. Fund management provided by Dmitry Radchenko agency. Despite the tremendous increase in understanding of basic cancer mechanisms and potential targets there has only been a moderate increase in effective new therapies to treat cancer.